Symbol not found

:AEON   00:00AM GMT
0.00 (0.00%)
Products, Regulatory

Aeon Biopharma Reports Results Of Mid-Stage Trial Of Abp-450 In Cervical Dystonia

Published: 09/23/2022 11:18 GMT
(AEON) - Aeon Biopharma Reports Positive Topline Results From Phase 2 Clinical Trial of Abp-450 (prabotulinumtoxina) in Cervical Dystonia.
Aeon Biopharma Inc - Phase 2 Trial Met Primary and Secondary Endpoints With Statistical Significance.
Aeon Biopharma - All 3 Dosing Arms Demonstrated Median Duration of Effect Greater Than Or Equal to 20 Weeks, Last Point at Which Patients Were Evaluated.
Aeon Biopharma Inc - End-of-phase 2 Meeting With FDA Expected in Q1 2023, and Plan to Initiate Phase 3 Program for Cd in 2023.
Aeon Biopharma Inc - Phase 2 Program With Abp-450 in Prevention of Both Chronic and Episodic Migraine is Actively Enrolling.
Aeon Biopharma Inc - Topline Data for Episodic Migraine Anticipated in Fall 2023.